[HTML][HTML] Targeting cyclin-dependent kinases in human cancers: from small molecules to peptide inhibitors

M Peyressatre, C Prével, M Pellerano, MC Morris - Cancers, 2015 - mdpi.com
Cyclin-dependent kinases (CDK/Cyclins) form a family of heterodimeric kinases that play
central roles in regulation of cell cycle progression, transcription and other major biological …

The role of non-coding RNAs in controlling cell cycle related proteins in cancer cells

S Ghafouri-Fard, H Shoorei, FT Anamag… - Frontiers in …, 2020 - frontiersin.org
Cell cycle is regulated by a number of proteins namely cyclin-dependent kinases (CDKs)
and their associated cyclins which bind with and activate CDKs in a phase specific manner …

Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity

RD Dorand, J Nthale, JT Myers, DS Barkauskas, S Avril… - Science, 2016 - science.org
Cancers often evade immune surveillance by adopting peripheral tissue–tolerance
mechanisms, such as the expression of programmed cell death ligand 1 (PD-L1), the …

The NAD‐dependent deacetylase sirtuin 2 is a suppressor of microglial activation and brain inflammation

TF Pais, ÉM Szegő, O Marques, L Miller‐Fleming… - The EMBO …, 2013 - embopress.org
Deleterious sustained inflammation mediated by activated microglia is common to most of
neurologic disorders. Here, we identified sirtuin 2 (SIRT2), an abundant deacetylase in the …

Biological functions of CDK5 and potential CDK5 targeted clinical treatments

A Shupp, MC Casimiro, RG Pestell - Oncotarget, 2017 - pmc.ncbi.nlm.nih.gov
Cyclin dependent kinases are proline-directed serine/threonine protein kinases that are
traditionally activated upon association with a regulatory subunit. For most CDKs, activation …

[HTML][HTML] Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity

H Deng, S Tan, X Gao, C Zou, C Xu, K Tu… - … Pharmaceutica Sinica B, 2020 - Elsevier
Blocking the programmed death-ligand 1 (PD-L1) on tumor cells with monoclonal antibody
therapy has emerged as powerful weapon in cancer immunotherapy. However, only a …

CDK5-dependent phosphorylation and nuclear translocation of TRIM59 promotes macroH2A1 ubiquitination and tumorigenicity

Y Sang, Y Li, Y Zhang, AA Alvarez, B Yu… - Nature …, 2019 - nature.com
Despite the development of adjuvant therapies, glioblastoma (GBM) patients remain
incurable, thus justifying the urgent need of new therapies. CDK5 plays a critical role in GBM …

Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance

G Ambrosini, CA Pratilas, LX Qin, M Tadi… - Clinical Cancer …, 2012 - aacrjournals.org
Purpose: Metastatic uveal melanoma represents the most common intraocular malignancy
with very poor prognosis and no effective treatments. Oncogenic mutations in the G-protein α …

[HTML][HTML] Tau protein as therapeutic target for cancer? Focus on glioblastoma

R Hedna, H Kovacic, A Pagano, V Peyrot, M Robin… - Cancers, 2022 - mdpi.com
Simple Summary Tau protein is a microtubule-associated protein, widely known for its role in
neurodegenerative diseases. Recent studies show that Tau can also be involved in the …

CDK5: an oncogene or an anti-oncogene: location location location

K Nikhil, K Shah - Molecular Cancer, 2023 - Springer
Recent studies have uncovered various physiological functions of CDK5 in many
nonneuronal tissues. Upregulation of CDK5 and/or its activator p35 in neurons promotes …